Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI7734 (Daxdilimab) in Autoimmune Diseases
NCT02780674Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dermatomyositis (DM), polymyositis (PM), Sjogren's syndrome and 2 more comparing MEDI7734 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Day 85. Started Aug 2016; status: completed.
02
Drugs
daxdilimab
03
Conditions
dermatomyositis (DM)polymyositis (PM)Sjogren's syndromesystemic lupus erythematosus (SLE)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT02780674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780674.